MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene, discovered in 2015. In mice it activates AMPK and improves insulin sensitivity, glucose handling and exercise capacity — which is where the "exercise mimetic" marketing comes from. There are no robust human trials. It is not approved as a medicine anywhere.
Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modelled on a fragment of bovine pineal-gland extract. It is not an approved medicine anywhere. The "telomerase activator" and "anti-ageing" claims trace almost entirely to a single Russian research group whose work has not been independently replicated in 25 years.
Both peptides share an evidence grade of D. The right choice depends less on the data and more on what you're trying to do — MOTS-c for insulin sensitivity, Epitalon for life extension (claimed).
Reproducible improvements in mouse models of obesity and high-fat-diet-induced insulin resistance. No controlled human trials in metabolic disease.
Older mice given MOTS-c ran further and longer in the 2021 Reynolds paper. The "exercise mimetic" claim rests almost entirely on this rodent work.
Rodent data suggest MOTS-c lowers myostatin and atrophy-related signalling. Not replicated in humans.
Reported in mouse and rat studies from the originating group. Not independently replicated.
Reported in human fibroblast cultures by Khavinson et al. (2003). The single most-cited mechanistic claim — and the one with the weakest independent confirmation.
A series of long-running clinical studies from the St. Petersburg / Kyiv groups report 28%–60% mortality reductions over 6–15 years. The trials were not blinded to modern standards, were conducted by the developers, and have not been replicated.
Long-term safety in humans is unknown — there are no large human clinical trials of MOTS-c. Short-term human safety data is essentially absent. Because MOTS-c affects mitochondrial signalling, AMPK and glucose handling, plausible concerns include hypoglycaemia (especially in anyone on insulin or sulfonylureas), interactions with metformin and other AMPK-active drugs, and unknown effects in cancer (AMPK signalling cuts both ways in tumour biology). Products sold as MOTS-c are unregulated research chemicals — purity, identity and dose-by-dose consistency are not guaranteed. People who are pregnant, breastfeeding, immunocompromised, diabetic, or taking other medicines should be especially cautious.
Long-term safety in humans is unknown. The published trials from the originating group report few adverse events, but those trials were small, unblinded, and run by the peptide's developers, so the safety signal is weak. A specific theoretical concern is telomerase activation: telomerase is upregulated in the majority of human cancers, and any agent that genuinely activates it carries a theoretical risk of accelerating the growth of existing tumours. This has not been demonstrated clinically but is a reasonable basis for caution in anyone with a cancer history. Products sold online as "Epitalon" are unregulated research chemicals — purity, sterility and dose-by-dose consistency are not guaranteed. People who are pregnant, breastfeeding, immunocompromised, have a cancer history, or take other medicines should be especially cautious.
Both peptides share an evidence grade of D. The right choice depends less on the data and more on what you're trying to do — MOTS-c for insulin sensitivity, Epitalon for life extension (claimed).
Pepwyse comparison pages are generated from the same structured data behind each peptide profile. Want a different head-to-head? Use the compare picker or ask MOTS-c directly via the Ask-Peppy button. Not medical advice — see how we grade evidence.